Welcome to the REVLIMID REMS™ program
REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy.
REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Important information about REVLIMID and the REVLIMID Risk Evaluation
and Mitigation Strategy (REMS)™ program
REVLIMID is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with REVLIMID provided adequate precautions are taken to avoid pregnancy
To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called "REVLIMID REMS™" (formerly known as the RevAssist® program)
Only prescribers and pharmacies certified by the REVLIMID REMS™ program can prescribe and dispense REVLIMID to patients who are enrolled and meet all the conditions of the REVLIMID REMS™ program
The goals of the REVLIMID risk evaluation and mitigation strategy are as follows:
To prevent the risk of embryo-fetal exposure to REVLIMID
To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for REVLIMID
REVLIMID® is a registered trademark of Celgene Corporation.
REVLIMID REMS™ is a trademark of Celgene Corporation.
©2013 year of origin. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.